Agios Pharmaceuticals
AGIO
156 hedge funds and large institutions have $1.36B invested in Agios Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 20 closing their positions.
153% more call options, than puts
Call options by funds: $18.2M | Put options by funds: $7.22M
70% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 20
35% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 43
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8% more funds holding
Funds holding: 144 → 156 (+12)
36% less capital invested
Capital invested by funds: $2.14B → $1.36B (-$780M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$35.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$8.89M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.57M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.49M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$5.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$36.8M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$23.9M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$5.41M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.15M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$2.35M |
AGIO Hedge Fund Activity: Q1 2016 in Review
156 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2016, worth a combined $1.36B — down 36% from $2.14B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AGIO positions and 20 closed out — a net gain of 14 holders — while 58 added to existing stakes and 43 trimmed.
The largest buyer was Millennium Management, adding an estimated $35.2M. The largest seller was First Trust Advisors, cutting an estimated $36.8M.
- 156 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2016, up from 144 in Q4 2015.
- Funds reported $1.36B of Agios Pharmaceuticals stock for Q1 2016, down 36% quarter-over-quarter.
- 34 funds opened new Agios Pharmaceuticals positions in Q1 2016 and 20 closed out, a net change of +14 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2016 was Millennium Management, an estimated $35.2M added.
- The largest Agios Pharmaceuticals seller in Q1 2016 was First Trust Advisors, an estimated $36.8M sold.
Based on aggregated 13F filings for Q1 2016.